Janux Therapeutics Inc Ordinary Shares JANX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if JANX is a good fit for your portfolio.
News
-
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
-
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
-
Janux Therapeutics Announces Proposed Public Offering of Common Stock
-
Thinking about buying stock in BigBear.ai, Janux Therapeutics, Surf Air Mobility, Bank of Nova Scotia, or Bellerophon Therapeutics?
-
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
-
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
Trading Information
- Previous Close Price
- $48.21
- Day Range
- $45.68–48.30
- 52-Week Range
- $5.65–58.69
- Bid/Ask
- $45.94 / $47.11
- Market Cap
- $2.43 Bil
- Volume/Avg
- 555,331 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 262.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 64
- Website
- https://www.januxrx.com
Comparables
Valuation
|
Metric
|
JANX
|
LYEL
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.48 | 0.89 | 0.78 |
Price/Sales | 262.53 | 4,440.15 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
JANX
|
LYEL
|
VOR
|
|---|---|---|---|
Quick Ratio | 26.40 | 15.82 | 8.81 |
Current Ratio | 26.80 | 16.07 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
JANX
LYEL
VOR
Profitability
|
Metric
|
JANX
|
LYEL
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −10.49% | −20.62% | −41.83% |
Return on Equity (Normalized) | −11.78% | −23.35% | −51.69% |
Return on Invested Capital (Normalized) | −15.13% | −24.46% | −47.03% |
Return on Assets
JANX
LYEL
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cspgnwydx | Hgjf | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zvmyfjzr | Qwpvnt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rqgjlptx | Bsxwzfy | $99.5 Bil | |
MRNA
| Moderna Inc | Hlvhjgzz | Tfzfr | $38.8 Bil | |
ARGX
| argenx SE ADR | Lwglckr | Qwg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nqvmxpszq | Nlbg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gnwcdpvrv | Zzdtgyk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hkshmjmb | Styrhck | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Srybpdgqvy | Rfdwrnb | $12.5 Bil | |
INCY
| Incyte Corp | Rxkszvsn | Gzhmrh | $11.6 Bil |